VEGFR2/KDR Antagonist – 1 mg

Overview

The VEGFR2/KDR Antagonist is a highly specific heptapeptide designed to bind to VEGFR2 (also known as KDR or flk) with precision. This interaction completely inhibits VEGF binding to KDR, effectively preventing VEGF-induced angiogenesis in vivo. This peptide serves as a powerful tool for researchers studying vascular biology and related fields.

Key Features

• Specific binding to VEGFR2 (KDR/flk)
• Inhibits VEGF binding, preventing vascular endothelial growth factor-induced angiogenesis
• Demonstrates significant inhibition of human endothelial cell proliferation in vitro
• Completely abolishes VEGF-induced angiogenesis in vivo
• Ideal for research applications in vascular biology and cancer studies

Specifications

FAQ

How does the VEGFR2/KDR Antagonist work?

The VEGFR2/KDR Antagonist binds specifically to the VEGFR2 receptor, blocking its ability to interact with VEGF. This action prevents the signaling cascade that leads to angiogenesis, making it a vital tool for studies focusing on vascular formation.

What applications can this peptide be used for?

This antagonist is primarily used in research settings to investigate the mechanisms behind angiogenesis and its role in diseases like cancer, where abnormal blood vessel formation plays a critical role in tumor growth and metastasis.

Is this product suitable for in vivo studies?

Yes, the VEGFR2/KDR Antagonist has shown effectiveness in vivo, making it suitable for studies that require assessing the impact of VEGF inhibition on angiogenesis in living organisms.

For related products, explore our PKG Substrateor check out our diverse selection of peptides designed for various research needs.

Related Products

• Autocamtide-2 [KKALRRQETVDAL]
• CREBtide [KRREILSRRPSYR], 5-FAM labeled